Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

AbCellera Biologics (ABCL) Long-Term Debt Repayments (2020 - 2021)

AbCellera Biologics' Long-Term Debt Repayments history spans 2 years, with the latest figure at $107000.0 for Q2 2021.

For the quarter ending Q2 2021, Long-Term Debt Repayments rose 272.58% year-over-year to $107000.0, compared with a TTM value of $1.8 million through Dec 2021, down 90.86%, and an annual FY2021 reading of $1.8 million, down 90.86% over the prior year.
Long-Term Debt Repayments for Q2 2021 was $107000.0 at AbCellera Biologics, down from $1.7 million in the prior quarter.
The five-year high for Long-Term Debt Repayments was $15.0 million in Q3 2020, with the low at -$62000.0 in Q2 2020.